Once-Versus Twice-Daily Tacrolimus

[1]  C. Cauffiez,et al.  Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients , 2011, Clinical pharmacokinetics.

[2]  G. Iaria,et al.  Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. , 2011, Transplantation proceedings.

[3]  D. Abramowicz,et al.  Conversion From Prograf to Advagraf Among Kidney Transplant Recipients Results in Sustained Decrease in Tacrolimus Exposure , 2011, Transplantation.

[4]  A. Karras,et al.  Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. , 2011, Transplantation proceedings.

[5]  P. Marquet,et al.  Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. , 2011, British journal of clinical pharmacology.

[6]  T. Slowinski,et al.  Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations , 2010, Pharmacogenetics and genomics.

[7]  R. Alloway,et al.  Four‐year experience with tacrolimus once‐daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies , 2011, Clinical transplantation.

[8]  B. Krämer,et al.  Tacrolimus Once Daily (ADVAGRAF) Versus Twice Daily (PROGRAF) in De Novo Renal Transplantation: A Randomized Phase III Study , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  D. Seehofer,et al.  Once‐Daily Prolonged‐Release Tacrolimus (ADVAGRAF) Versus Twice‐Daily Tacrolimus (PROGRAF) in Liver Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  A. Prémaud,et al.  Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation , 2010, Clinical pharmacokinetics.

[11]  J. Morales,et al.  Extended-release tacrolimus therapy in de novo kidney transplant recipients: single-center experience. , 2010, Transplantation proceedings.

[12]  V. López,et al.  Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. , 2010, Transplantation proceedings.

[13]  A. Castro‐Beiras,et al.  Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase. , 2010, Transplantation proceedings.

[14]  K. Verbeke,et al.  Reduced C0 Concentrations and Increased Dose Requirements in Renal Allograft Recipients Converted to the Novel Once-Daily Tacrolimus Formulation , 2010, Transplantation.

[15]  P. Berloco,et al.  Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. , 2010, Transplantation proceedings.

[16]  M. Merli,et al.  Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. , 2010, Transplantation proceedings.

[17]  M. Faraci,et al.  Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. , 2010, Transplantation proceedings.

[18]  P. Marquet,et al.  Pharmacokinetic Modeling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving the Tacrolimus Once-Daily Formulation , 2010, Therapeutic drug monitoring.

[19]  J. Squifflet,et al.  Pharmacokinetics for Once‐ Versus Twice‐Daily Tacrolimus Formulations in De Novo Kidney Transplantation: A Randomized, Open‐Label Trial , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  L. Marín-Gómez,et al.  Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. , 2009, Transplantation proceedings.

[21]  J. Pérez-Martínez,et al.  Conversion to tacrolimus extended-release formulation: short-term clinical results. , 2009, Transplantation proceedings.

[22]  M. Mir,et al.  De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. , 2009, Transplantation proceedings.

[23]  V. Haufroid,et al.  Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.

[24]  M. A. Alonso Álvarez,et al.  Three-month experience with tacrolimus once-daily regimen in stable renal allografts. , 2009, Transplantation proceedings.

[25]  S. Chandy,et al.  A limited sampling strategy for tacrolimus in renal transplant patients. , 2008, British journal of clinical pharmacology.

[26]  A. Woywodt,et al.  Different Preparations of Tacrolimus and Medication Errors , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  M. First.  First Clinical Experience With the New Once-Daily Formulation of Tacrolimus , 2008, Therapeutic drug monitoring.

[28]  Roberto Canaparo,et al.  EXPRESSION OF CYP3A ISOFORMS AND P‐GLYCOPROTEIN IN HUMAN STOMACH, JEJUNUM AND ILEUM , 2007, Clinical and experimental pharmacology & physiology.

[29]  J. Melancon,et al.  Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. , 2007, Transplantation.

[30]  M. Pescovitz,et al.  Once‐Daily Tacrolimus Extended‐Release Formulation: 1‐Year Post‐Conversion in Stable Pediatric Liver Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  A. Matas,et al.  Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. , 2007, Transplantation.

[32]  P. Kuo,et al.  One‐Year Results with Extended‐Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  C. Cantarell,et al.  Evaluation of a Limited Sampling Strategy to Estimate Area Under the Curve of Tacrolimus in Adult Renal Transplant Patients , 2005, Therapeutic drug monitoring.

[34]  A. Israni,et al.  Impact of Simultaneous Kidney–Pancreas Transplant and Timing of Transplant on Kidney Allograft Survival , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  S. Florman.  CONVERSION OF STABLE LIVER TRANSPLANT RECIPIENTS FROM A TWICE DAILY PROGRAF BASED REGIMEN TO A ONCE DAILY MODIFIED RELEASE TACROLIMUS BASED REGIMEN , 2004, Transplantation proceedings.

[36]  R. Alloway.  CONVERSION OF STABLE KIDNEY TRANSPLANT RECIPIENTS FROM A TWICE DAILY PROGRAF BASED REGIMEN TO A ONCE DAILY MODIFIED RELEASE TACROLIMUS BASED REGIMEN , 2004, Transplantation proceedings.

[37]  M. First,et al.  Modified release tacrolimus. , 2004, Yonsei medical journal.

[38]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[39]  Tetsuro Kato,et al.  Chronopharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Occurrence of Acute Rejection , 2003, Journal of clinical pharmacology.

[40]  T. Pisitkun,et al.  The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. , 2002, Transplantation proceedings.

[41]  N. Undre,et al.  Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. , 2002, Transplantation proceedings.

[42]  J. Poulsen,et al.  C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  J. V. van Hooff,et al.  Trough levels of tacrolimus. , 2002, Therapeutic drug monitoring.

[44]  M. Kimikawa,et al.  Effective oral administration of tacrolimus in renal transplant recipients , 2001, Clinical transplantation.

[45]  V. Armstrong,et al.  Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. , 2001, Transplantation proceedings.

[46]  S. Ozono,et al.  Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). , 2001, Transplantation proceedings.

[47]  C. Shek,et al.  Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  N. Kneteman,et al.  Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). , 1999, Transplantation.

[49]  J. Barkun,et al.  Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. , 1998, Transplantation proceedings.

[50]  Wojciech Piekoszewski,et al.  Pharmacokinetics of tacrolimus in liver transplant patients , 1995, Clinical pharmacology and therapeutics.